MYND Life Sciences Inc. Granted Management Cease Trade Order
MYND Life Sciences Inc. Granted Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announces that it has been advised by its external auditors (the "Auditors") that they will not be in a position to complete their work on the Company's annual consolidated financial statements for the year ended October 31, 2022 (the "2022 Financial Statements") prior to the filing deadline of February 28, 2023 (the "Annual Filing Deadline"). As a result, the Company will not be able to file the 2022 Financial Statements, accompanying Management Discussion & Analysis and CEO and CFO certifications, and the Annual Information Form (collectively, the "2022 Annual Filings") prior to the Annual Filing Deadline as required under applicable Canadian securities laws. The Company anticipates filing the 2022 Financial Statements by March 31, 2023.
温哥华，不列颠哥伦比亚省-(Newsfile Corp.-2023年3月1日)-MyND生命科学公司。本公司(CSE：MYND)(以下简称“MyND”或“本公司”)宣布，其外聘核数师(“核数师”)已告知本公司，他们将无法在截止日期2023年2月28日(“年度提交截止日期”)之前完成本公司截至2022年10月31日止年度综合财务报表(“2022年财务报表”)的编制工作。因此，根据适用的加拿大证券法的要求，公司将无法在年度申报截止日期之前提交2022年财务报表、随附的管理层讨论和分析以及CEO和CFO证书，以及年度信息表(统称为“2022年年度申报”)。该公司预计在2023年3月31日之前提交2022年财务报表。
The Company further announces that it has been granted a management cease trade order (MCTO) under National Policy 12-203 of the Canadian Securities Administrators ("NP 12-203") imposed against certain insiders of the Company. The MCTO will remain in effect until the Company has filed its audited statements and the Executive Director of the BCSC has revoked the order. The Company will be required to comply with the provisions of the alternative information guidelines as set out in NP 12-203 for so long as the MCTO remains in effect, including the issuance of bi-weekly default status reports by way of press releases.
本公司进一步宣布，根据加拿大证券管理人(“NP12-203”)针对本公司某些内部人士实施的国家政策12-203，本公司已获授予管理停止交易令(MCTO)。在本公司提交其经审计的报表且BCSC的执行董事已撤销订单之前，MCTO将继续有效。只要MCTO仍然有效，本公司将被要求遵守NP 12-203中规定的替代信息指南的规定，包括以新闻稿的方式发布两周一次的违约状态报告。
The Company will make further announcements with respect to the status of the 2022 Annual Filings as and when appropriate.
公司将在适当的时候就2022年年报的状况发布进一步的公告。
ABOUT MYND LIFE SCIENCES INC.
关于我的生命科学公司。
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.
我的名字生命科学公司是一家专注于神经药物和新药开发、诊断和疫苗的医用生物技术药物研究和开发公司。我的名字正在开发新的生物实体(NBE)和新的化学实体(NCE)，并通过克服疾病的独特分子概念将自己与其他(生物)制药公司区分开来。该公司通过严格的科学和临床试验推动药物开发，同时努力申请专利并保护其知识产权。
Contact:
Dr. Lyle Oberg, MD, CEO
Email: ir@myndsciences.com
Phone: 780 965-0122
Web:
联系方式：
Lyle Oberg博士，医学博士，首席执行官
电子邮件：ir@myndcerences.com
电话：780965-0122
网页：
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问